552c7ae14ClaimDiet and exercise interventions alone are not enough to reverse the rise in childhood obesityAgreeDisagree31
552c7ae14ClaimWeight-loss medications are appropriate as a first-line treatment for adolescents with obesityAgreeDisagree
552c7ae14ClaimYounger patients should receive priority when lifesaving treatment is scarceAgreeDisagree2
552c7ae14ClaimThe metabolic health benefits of GLP-1 drugs outweigh their dermatological side effectsAgreeDisagree
552c7ae14ClaimMedicare coverage of anti-obesity drugs would add about $35 billion to federal spending from 2026 to 2034AgreeDisagree
552c7ae14ClaimSemaglutide carries a regulator-confirmed risk of NAION, a very rare optic nerve conditionAgreeDisagree
552c7ae14ClaimSemaglutide and tirzepatide are cost-effective for obesity at current net pricesAgreeDisagree
552c7ae14ClaimMost adults with obesity but without diabetes stop GLP-1 drugs within a yearAgreeDisagree
552c7ae14ClaimMedicare coverage of weight-loss drugs could save Medicare $175–245 billion over ten yearsAgreeDisagree
552c7ae14ClaimPlacebo-controlled trials should be required before approving new medicinesAgreeDisagree
552c7ae14ClaimNew medicines should have to outperform existing treatments before approvalAgreeDisagree
552c7ae14ClaimGovernments should license publicly funded drug patents to competitors when prices are unaffordableAgreeDisagree